Investment in better health for all
European venture capital investment is the fuel for life-saving treatments and medical devices, as well as innovative digital solutions that are altering the face of global health services. VC investment in European Biotech & Healthcare has grown strongly since the financial crisis, reaching new highs in the wake of the pandemic. Furthermore, investment has proved resilient through periods of economic growth and contraction, underlining European Life Sciences’ crucial role whatever the macro conditions.
Invest Europe data shows an industry that is breaking new ground across the continent. Venture capital investment helped Norway’s Algeta develop novel alpha-particle emitting therapies for the treatment of cancer, and Ireland’s Inflazome to address the unmet clinical needs of inflammatory illnesses. There are few other sectors in which venture capital investment can have such a direct and beneficial impact on millions of lives.
Venture stage investments 2007-21
Investments 2017-21
Investments 2017-21
Biotech & Healthcare sector, Venture stage companies, by geography
